Cleavable linkers for the reduction of non-target organ retentio

Details Cleavable linkers for the reduction of non-target organ retentio Cleavable linkers for the reduction of non-target organ retentio

1992-02-10

1992-12-15

Stoll, Robert L.

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

424 9, 424 4, 424 71, 424 8591, 424 9463, 424 9464, 424717, 424720, 514474, 514562, 514836, 514922, 5303911, 5303915, 5303919, 530402, 530807, A61K 4902, A61K 4900, A61K 3700, A61K 39395

Patent

active

051715635

ABSTRACT:
A process for reducing the non-target organ accumulation of immunoconjugates administered in vivo during therapeutic or diagnostic procedures involves the use of immunoconjugates comprising linkers that are cleavable at the non-target organs. The linkers are cleavable under conditions present, or induced, at one or more non-target organs, which include the kidneys or the liver.

REFERENCES:
patent: 4081246 (1978-03-01), Polito et al.
patent: 4110432 (1978-08-01), Wilkinson et al.
patent: 4232119 (1980-11-01), Carlsson et al.
patent: 4340535 (1982-06-01), Voisin et al.
patent: 4511501 (1985-04-01), Luduena
patent: 4569789 (1986-02-01), Blattler et al.
patent: 4625014 (1986-11-01), Senter et al.
patent: 4631190 (1986-12-01), Shen et al.
patent: 4643895 (1987-02-01), Casellas et al.
patent: 4647671 (1987-03-01), Schwartz
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4698420 (1987-10-01), Urnovitz
patent: 4849511 (1989-07-01), Verbruggen
patent: 4867962 (1989-09-01), Abrams
patent: 4867973 (1989-09-01), Goers et al.
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4952394 (1990-08-01), Senter
patent: 4981979 (1991-01-01), Sivam
patent: 4997913 (1991-03-01), Hellstrom et al.
International Search Report for International Application No. PCT/US89/04266.
Meares et al, Intl. J. Cancer [Suppl] (United States) 1988, 2 pp. 99-102, "Chelate Radiochemistry: cleavable linkers lead to altered levels of radioactivity in the liver".
Blakely et al, Antibody, Immunoconjugates, and Radiopharmaceuticals, vol. 1, Nov. 1, 1988, pp. 1-16, "An Overview of Therapy with Immunotoxins Containing Ricin or Its A-Chain".
Deshpande et al, Int. J. Rad. Appl. Instrum. [B] (England) 1989, 16 (6) pp. 587-597, "Effect of Different Linkages Between Chelates and Monoclonal Antibodies on Levels of Radioactivity in the Liver".
Haseman et al, European J. Nucl. Med. (1986) 12:455-460, "Metabolizable 111 In chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice".
Bundgaard et al, J. Med. Chemistry, 1987, 30, pp. 451-454, "Esters of N,N-Disubstituted 2-Hydroxyacetamides as a Novel Highly Biolabile Prodrug Type for Carboxylic Acid Agents".
Blattler et al, Biochemistry, 1985, 24, 1517-1524, "New Heterobifunctional Protein Cross-Linking Reagent That Forms an Acid-Labile Link".
Worrell et al, Anti-Cancer Drug Design (1986), 1, pp. 179-188, "Effect of Linkage Variation on Pharmacokinetics of Ricin A Chain-Antibody Conjugates in Normal Rats".
Goodwin et al, J. Nucl. Med. (Jun., 1986) vol. 27, No. 6, p. 959, Abstract 336.
Quadri et al, J. Nucl. Med. (Jun., 1986) vol. 27, No. 6, p. 959, Abstract 337.
Goodwin et al, Nucl. Med. Biol. (1986) vol. 13, NO. 4, pp. 383-391, "Monoclonal Antibodies as Reversible Equilibrium Carriers of Radiopharmaceuticals".

Affiliated with

Also associated with

Rating

Cleavable linkers for the reduction of non-target organ retentio does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cleavable linkers for the reduction of non-target organ retentio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cleavable linkers for the reduction of non-target organ retentio will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2091411